{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 24 of 169', '4) The eDiary consists of (i) Eczema-related Sleep NRS, (ii) Worst Daily Pruritus NRS, (iii) Average Daily Pruritus NRS, (iv) PGI-B, and (v) PGI-S.', '5) Optional, selected trial sites only.', 'ADA, anti-drug antibodies; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; EASI50, at least 50% reduction in EASI score;', 'EASI75, at least 75% reduction in EASI score; ECG, electrocardiogram; eDiary, electronic diary; EQ-5D-5L, EuroQoL 5-Dimension Health Questionnaire', \"5 Level; HADS, Hospital Anxiety and Depression Scale; IGA, Investigator's Global Assessment; IgE, immunoglobulin E; IMP, investigational medicinal product;\", 'NRS, numeric rating scale; PGI-B, Patient Global Impression of Bother; PGI-S, Patient Global Impression of Severity; POEM, Patient Oriented Eczema Measure;', 'Q2W,', 'every', '2', 'weeks; SCORAD, Scoring Atopic Dermatitis; SF-36, 36-Item Short Form Health Survey; TCS, topical corticosteroids; TSQM, Treatment', 'Satisfaction Questionnaire for Medication; WPAI-GH, Work Productivity and Activity Impairment - General Health.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 25 of 169', 'Panel 4 Schedule of trial procedures: open-label tralokinumab and follow-up', 'Open-label tralokinumab treatment', 'FU1\u00b2', 'Visit', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', '26', '27', '28', '29', '301', '31', 'Week', '18', '20', '22', '24', '26', '28', '30', '32', '34', '36', '38', '40', '42', '44', '46', '48', '50', '52', '66', 'Visit window (days)', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', 'Trial population and eligibility (Section 8 and Appendix 4B)', 'Informed consent (home-use)\u00b3', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Trial products (Section 9)', 'IMP administration and compliance', 'X4', 'X4', 'X4', 'X4', 'X4', 'X4', 'X4', 'X4', 'X4', 'X4', 'X4', 'X4', 'X4', 'X4', 'X4', 'X4', 'X4', 'X4,5', 'Concomitant medications/procedures', 'X', 'X', 'X6', 'X', 'X6', 'X', 'X6', 'X', 'X6', 'X', 'X6', 'X', 'X6', 'X', 'X6', 'X', 'X6', 'X', 'X', 'Investigator assessments of efficacy (Section 10.3.1)', 'IGA', 'X', 'X', 'X', 'X', 'X', 'X', 'EASI', 'SCORAD', 'X', 'X', 'X', 'X', 'Safety assessments (Sections 10.4 and 11)', 'Vital signs', 'X4', 'X4', 'X4,6', 'X4', 'X4,6', 'X4', 'X4,6', 'X4', 'X4,6', 'X4', 'X4,6', 'X4', 'X4,6', 'X4', 'X4,6', 'X4', 'X4,6', 'X', 'Physical examination', 'X', 'ECG', 'X', 'Urine pregnancy test', 'X', 'X', 'X', 'Serum chemistry, haematology, and IgE', 'X', 'Urinalysis', 'X', 'Pharmacokinetics', 'X', 'ADA', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}